Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764284 | 0.81 | KDM4E (0.47) | DUT | |
| SCHEMBL24346162 | 0.81 | — | — | |
| SCHEMBL1392926 | 0.79 | MEN1 (0.38) | DUT | |
| SCHEMBL16769196 | 0.79 | DUT (0.37) | DUT | |
| SCHEMBL4416507 | 0.79 | PTGER4 (0.38) | — | |
| SCHEMBL25259763 | 0.78 | DUT (0.36) | DUT | |
| SCHEMBL673626 | 0.78 | DUT (0.36) | DUT | |
| SCHEMBL24579070 | 0.78 | DUT (0.36) | DUT | |
| SCHEMBL16784470 | 0.78 | DUT (0.36) | DUT | |
| SCHEMBL26015708 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119343353-A | 2-Methyl-4 ',5' -dihydrospiro [ piperidine-4, 7' -thieno [2,3-c ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4476227-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4476228-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119013281-A | 4',5' -Dihydrospiro [ piperidine-4, 7' -thieno [2,3-C ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3512858-B1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3555103-B1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-29 | — | — | US | disclosed |
| US-10745409-B2 | Azepane inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-18 | — | — | US | disclosed |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190322685-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceultica nv (BE) | 2019-07-18 | — | — | US | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
| WO-2018050684-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | DUT 3224/4885 |
| US-10745409-B2 | Azepane inhibitors of menin-MLL interaction | MEN1, MLLT1, BMI1 | DUT 2734/4885 |
| US-20190322685-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | MEN1, MLLT1, BMI1 | DUT 2734/4885 |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, MEN1 | DUT 3540/4885 |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | DUT 3224/4885 |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | DUT 3224/4885 |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | DUT 3224/4885 |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | MEN1, MLLT1, BMI1 | DUT 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.